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Summary During the period 1974-89, 169 children with Hodgkin's disease were treated in the Paediatric
Oncology Units of the Royal Marsden and St Bartholomew's Hospitals. The overall actuarial survival for the
whole group was 81% at 10 years. Thirty-five of the 169 children either did not achieve a complete remission
or subsequently relapsed. The estimated actuarial survival from initial relapse or failure of primary treatment
was 60% at 5 years and 45% at 10 years. Over half of the patients requiring salvage therapy had declared
themselves within 2 years and only 3 relapses occurred more than 3 years from diagnosis. Very few patients
remain disease free long term after failure of primary and initial salvage therapy. Patients relapsing within a
year of diagnosis or not achieving a complete response to primary therapy and those with disseminated relapse
had a poor response to salvage therapy. A significant subgroup of patients had prolonged survival despite
multiple relapses. Neither initial histology nor stage affected survival from relapse although numbers in each
subgroup were small.
There are approximately 70 new cases of Hodgkin's Disease
(HD) annually in the UK in children under the age of 15
years. The overall 5-year survival rate in this age group (all
stages) is in excess of 80%. This figure falls with increasing
age to less than 40% for those over 65 years at diagnosis
(Kennedy et al., 1985). Whilst factors predictive of relapse in
both adults (Kennedy et al., 1985) and children (Mauch et
al., 1983; Robinson et al., 1984; Russell et al., 1984); are well
documented, there have been few studies looking at prognos-
tic factors for those patients who relapse following primary
therapy. We have undertaken a study of all children treated
at the Royal Marsden and St Bartholomew's Hospitals dur-
ing the period 1974-89, during which time common primary
treatment programmes were in operation. In this paper we
report our experience with relapsed or resistant HD and
identify factors predictive of response to salvage treatment.
Eighty-four of these patients have been previously analysed
to assess factors predictive of a poor response to primary
treatment (Robinson et al., 1984).
Methods
During the period 1974-89, a total of 169 patients aged less
than 16 years were treated for HD. Of these patients, 35
either did not achieve a complete remission or subsequently
relapsed and are the subject of this analysis. Treatment
policies have changed over the study period as outlined
below. Early stage cases (stage IA and some IIA) received
primary radiotherapy either to involved sites only or to a full
mantle to a dose of 35 Gy in 20 fractions sometimes with a
boost to sites of bulk disease. During the period 1974-77,
these early stage cases also received 3 courses of chemo-
therapy. Between 1974 and 1986, primary chemotherapy for
HD comprised combination chemotherapy with chloram-
bucil, vinblastine, procarbazine, prednisolone (CHLVPP)
(Kaye et al., 1979). From 1987, in an effort to preserve
fertility this regimen was replaced by vincristine, epirubicin,
etoposide and prednisolone (VEEP) (Pinkerton et al., 1988).
The indications for radiotherapy as sole treatment remained
unchanged. Between 1974 and 1990 patients with bulky
mediastinal disease received adjuvant mediastinal radio-
therapy to a dose of 25-35 Gy in 15-20 fractions (Glynne-
Jones et al., 1990). More recently, patients with IIA disease
just involving upper cervical nodes have received radio-
therapy alone.
A wide variety of salvage regimens were employed during
the study period including prednisolone, doxorubicin, vincris-
tine and etoposide (HOPE), HOPE + bleomycin (HOPE-
BLEO), chlorambucil, etoposide and CCNU (LEC), high-
dose melphalan with or without etoposide and BCNU
followed by autologous bone marrow transplantation (AB-
MT), doxorubicin, bleomycin, vincristine and dacarbazine
(ABVD), VEEP and CHLVPP with or without radiotherapy.
The details of the stage, histology, primary and salvage
treatments of the 35 patients at presentation are shown in
Tables I-IV.
The effects of various parameters on the response to sal-
vage treatment were determined using the log-rank method
(Kaplan & Meir, 1958), multivariate analysis was by Cox
regression (Cox, 1972). In order to simplify the analysis,
remission duration was defined as the time from commence-
ment of treatment to the date at which the treatment was
deemed to have failed and thus includes patients who did not
respond. In those cases in whom the disease clearly was not
responsive this is presented as a very short 'remission'. This
approach, whilst not strictly accurate, allows resistant and
relapsed disease to be analysed together rather than in
separate subgroups which would have resulted in very
fragmented data. Where there are sufficient data, these two
groups have been analysed separately.
Table I Patient characteristics
Relapsed/resistant
Allpatients patients
Stage number (%) number (%)
IA 28 (21.1) 4 (11.4)
2A 46 (34.6) 12 (34.3)
2B 12 (9) 3 (8.6)
3A 13 (9.8) 5 (14.3)
3AS 8 (6.0) 0
3B 3 (2.3) 1 (2.9)
3BS 5 (3.8) 2 (5.7)
4A 3 (2.3) 1 (2.9)
4B 15 (11.3) 7 (20.0)
Total number of patients = 169. Of these, 35 patients relapsed
(n = 32) or had resistant disease (n = 3); 25 (71%) male, 10 (29%)
female.
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Table II Patient characteristics-histology
Relapsed/resistant
Allpatients patients
Histology number (%) number (%)
Lymphocyte 23 (17.3) 2 (5.7)
predominant
Nodular sclerosing 34 (25.6) 11 (31.4)
Mixed cellularity 27 (20.3) 9 (25.7)
Lymphocyte depleted 3 (2.3) 3 (8.6)
Nodular sclerosing/ 30 (22.6) 5 (14.3)
mixed cellularity
Mixed/unclassified 14 (10.5) 5 (14.3)
Total 133 35
Table III Primary treatment
RTdose range
in gray
Treatment Number (%) (2 Gy/fraction)
Radiotherapy only:
Involved field 5 (14.3) 35-40
Mantle 1 (2.9) 40
Chemotherapy only:
CHLVPP 11 (31.4)
VEEP 2 (5.7)
ABVD 1 (2.9)
Combined therapy:
CHLVPP + mediastinum 1 (2.9) 40
CHLVPP +'Urn' 4 (11.4) 25-35
CHLVPP + mantle 8 (22.8) 35-40
CHLVPP + TNI 2 (5.7) 35
Total 35
Table IV Salvage therapy
Drug Chemotherapy
Regimen only Radiotherapy
ABVD 7 3
PAVE 10 6
CHIVPP 10 2
LEC 5 2
None 1 2
Results
Details of initial stage and histology are shown in Tables I
and II respectively, together with relapse rates for the various
subgroups. Tables III and IV show the primary and salvage
treatment received by the 35 children reported in this study.
The overall actuarial survival for the whole patient group
at 10 years was 81% (Figure 1). Figure 2 shows the distribu-
tion of time to relapse in the 35 children who failed first line
therapy and Figure 3 shows the overall actuarial survival
from initial relapse or failure of primary treatment. The
estimated 5 and 10 year actuarial survival rates are 60% and
45% respectively from time of relapse. Following initial
therapy, over half of the patients requiring salvage treatment
had declared themselves within 2 years and only three
relapses occurred after 3 years. The actuarial risk of early
relapse defined as relapse within 2 years of diagnosis and
including patients with primary treatment failure is 20% and
the risk of late relapse 3%. The overall proportion disease
free after salvage treatment is approximately 45% with very
few patients remaining disease free long term after failure of
primary and initial salvage (Figure 4).
The effect of the quality and duration of the response to
primary therapy is shown in Figures 5 and 6. Patients who
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Figure 3 Overall survival from first relapse or treatment failure.
relapsed within a year or who did not achieve a complete
response to primary therapy had a poor response to salvage
therapy, with a probability of less than 1 in 5 of remaining
disease free 2 years from the salvage therapy. The overall
survival according to number of relapses is shown in Figure
7. For patients experiencing a single relapse, the actuarial
survival at 8 years is 60%; with two relapses this falls to
30%. Patients relapsing on three or more occasions had an
actuarial survival at 8 years of approximately 50%, the
differences being non-significant (P=0.13).
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Figure 4 Disease-free survival from salvage treatment. Upper
curve, first salvage treatment, n = 35; lower curve, second salvage
treatment, n = 14. X2 = 6.582, P = 0.010.
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Figure 7 Overall survival according to number of relapses.
Upper curve, single relapse, n = 21; lower curve 2 or more
relapses, n = 14. x2 = 1.723, P = 0.189.
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Figure 5 Second remission duration according to response to
primary treatment. Upper curve, CR to primary treatment,
n = 32; lower curve, no CR to primary treatment n = 3.
x2 = 7.677, P = 0.006.
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Figure 8 Overall survival according to distribution of disease at
relapse. Upper curve, local relapse only, n = 13; lower curve,
disseminated disease at relapse, n = 14. x2 = 8.660, P = 0.003.
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Figure 6 Disease-free survival according to first remission dura-
tion. Upper curve, first remission longer than 1 year; lower curve,
first remission less than I year. x2 = 9.933, P = 0.002.
Neither initial histology, stage nor primary therapy (data
not shown) had any effect on survival from relapse, although
the numbers in each category were small. The effect of site of
relapse in relation to the primary disease is shown in Figure
8. Patients relapsing only at the site of primary disease had
an actuarial disease free survival (DFS) of 90% at 5 years
and 80% at 10 years. Patients relapsing both within and
without the original sites of disease had a very poor prog-
nosis with no patients alive 3 years from salvage treatment
(disseminated relapse on Figure 8). Of patients relapsing at
distant sites only, survival at 3 years was approximately 85%,
too few patients in this category have been followed up
beyond 3 years to comment further. The differences between
these groups were significant (P<0.001). There were
insufficient patients to determine the effect of relapse in
extra-lymphatic sites (including the liver).
Discussion
Despite improvements in the overall prognosis for both
adults and children with Hodgkin's disease, a proportion of
patients are not cured by their primary treatment. This study
attempts to identify factors predictive of the outcome of
salvage therapy which may thus aid in the construction of
salvage regimens.
The pattern of relapse in childhood Hodgkin's disease
appears to differ from that observed in adult patients in
several aspects. Firstly, the overall relapse rate (all stages) of
21% is lower than that seen in adult populations. For exam-
ple, over the same time period, the Royal Marsden Hospital
reported a relapse rate of over 30% for stage I and II adult
patients (Duchesne et al., 1989). Secondly, the incidence of
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late relapse (5.4% after 3 years) observed in this series, is low
compared with rates of the order of 10-15% reported in
series of adult patients (Duchesne et al., 1989). Indeed the
majority of patients with either resistant or relapsed disease
had declared themselves by 2 years with few relapses (20%)
occurring after this time. A similar pattern appears to be
repeated in second and third remissions with the majority of
relapses occurring within 2 years and only three relapses
occurring beyond 3 years (Figure 2). Thus it appears that a
patient in remission 2 years after their last treatment is very
likely to be cured. This was formerly thought to be the case
with adult HD (Herman et al., 1985) but more recently,
improved primary treatment has reduced the risk of early
relapse so that the risk of relapse 3-6 years from treatment
is of similar magnitude to the risk of relapse in the first 3
years (Duchesne et al., 1989).
Surprisingly, initial histology and stage appeared to have
little predictive value following an initial relapse, although
numbers in each category were small. Conversely, site of
relapse has a strong predictive value (Figure 8), with those
patients re-presenting with both local and distant disease
doing very badly whereas patients with failure of local con-
trol only fare very well. Patients failing only at distant sites
had an intermediate prognosis. These findings are in keeping
with other studies of relapsed HD. For instance, Roach et al.
(1990) found stage at relapse but not initial stage or histology
to be important prognostic indicators in a study of 109
adults with relapsed HD. Colby et al. (1981) found no
difference in salvage rates with different histologies in a study
of 659 patients.
Patients who do not achieve a complete response with
primary therapy or in whom the response lasts less than a
year were unlikely to achieve a durable remission with stan-
dard salvage regimens as employed in the patients reported
here (see Figures 5 and 6). Patients with primary resistant
disease have a poor prognosis but (fortunately) are rare.
Patients achieving a partial response to primary therapy or
relapsing rapidly after a complete response have chemosen-
sitive or radiosensitive disease and are probably good can-
didates for some form of intensive therapy in an effort to
achieve a durable complete response. It may thus be appro-
priate to consider some form of megatherapy as part of a
salvage regimen in such patients if they respond to initial
cytoreductive therapy (Applebaum et al., 1987).
There remains a subgroup of patients not falling in these
categories who nonetheless fail to achieve a durable remission
despite multiple retreatments (Figure 7). This subgroup had a
50% survival rate at 5 years, although probably few of these
patients will be long-term survivors. This persistently relaps-
ing subgroup may have a form of HD with a relatively
drug-resistant phenotype analogous to follicular lymphoma
and so a good response to more intensive therapy may be
less likely than the overall drug sensitivity of HD would
indicate. Alternatively, these patients may benefit from more
aggressive therapy, the case for which is argued persuasively
by De Vita et al. (1987) and Hryniuk (1988).
In conclusion, current therapeutic approaches are effective
in a large proportion ofcases either at the outset (79%) or at
first relapse (45%). However, there remain three subgroups
who do badly:
(1) Patients with drug-resistant aggressive disease who
relapse early or who fail to respond to initial treatment and
whose survival is short.
(2) Patients who respond but relapse early or with widely
disseminated disease.
(3) Patients with indolent relapsing disease with good sur-
vival but non-durable remissions.
The first group has a poor survival with conventional
salvage regimens, and optimal treatment is problematical.
The second group has chemosensitive disease and it may
be appropriate to consider some form of megatherapy early
on in their salvage treatment after initial cytoreductive
therapy. The appropriate therapy for the third group is
unclear and it is unlikely that clinical trials will be able to
provide readily an answer in view of the relatively good
overall survival observed and small numbers of patients
involved. In contrast, a trial may be able to provide rapid
results in the first two groups as the patients can be readily
identified and their anticipated survival is short.
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